Skip to main content
SpringerLink
Log in

Functional Imaging of Neuroendocrine Tumors

  • Protocol
  • First Online:
Positron Emission Tomography

Part of the book series: Methods in Molecular Biology ((MIMB,volume 727))

Abstract

Neuroendocrine tumors (NET) have several distinct pathophysiological features that can be addressed by specific radiolabeled probes. An overview on the different radiopharmaceuticals that have been developed for positron emission tomography (PET) of NET are presented. The focus is on fluordeoxyglucose (F-18 FDG), biogenic amine precursors, somatostatin analogs, and hormone syntheses markers. Due to the highly specific tracers lacking any clear anatomical landmarking, the advantages of integrated functional and morphological imaging systems such as PET-CT are obvious. Based on the up to now published literature and one’s own experience, it is concluded that amine precursors (e.g. fluor-dihydroxyphenylalanin and hydroxytryptophane) should be employed in most gastroenteropancreatic NET, whereas F-18 FDG should be preserved for more aggressive less-differentiated NETs. Hormone syntheses markers have up to now only been used in few centers and their broad clinical value remains uncertain. The different available somatostatin analogs are the most promising tracers, since they can improve dosimetry in cases where peptide receptor radiotherapies are planned. Of specific interest are the somatostatin analogs addressing several subtypes of the somatostatin receptor (e.g. DOTANOC) that allow detecting also subtypes not expressing the “classically” addressed subtype 2 and 5. Since NET have a high variety of different features, the individual diagnostic approach using PET or integrated PET-CT should be tailored, depending on the histological classification and the differentiation of the tumor.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 119.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Sundin, A., Garske, U., Örlefors, H. (2007) Nuclear imaging of neuroendocrine tumors Best Pract Res Clin Endocrinol Metab 21, 69–85.

    Article  PubMed  CAS  Google Scholar 

  2. Pearse, A.G. (1968). Common cytochemical and ultrastructural characteristics of cells producing polypeptide hormones (the APUD series) and their relevance to thyroid and ultimobranchial C cells and calcitonin Proc R Soc Lond B Biol Sci 170(18), 71–80.

    Article  PubMed  CAS  Google Scholar 

  3. Pearse, A.G. (1980). The APUD concept and hormone production Clin Endocrinol Metab 9(2), 211–22.

    Article  PubMed  CAS  Google Scholar 

  4. Reubi, J.C. (2003). Peptide receptors as molecular targets for cancer diagnosisand therapy Endocr Rev 24(4), 389–427.

    Article  PubMed  CAS  Google Scholar 

  5. Patel, R.C., Kumar, U., Lamb, D.C.,et al.(2002) Ligand binding to somatostatin receptors induces receptor-specific oligomer formation in live cells Proc Natl Acad Sci U S A 99(5), 3294–9.

    Article  PubMed  CAS  Google Scholar 

  6. Patel, Y.C., Greenwood, M.T., Panetta, R., Demchyshyn, L., Niznik, H., Srikant, C.B. (1995) The somatostatin receptor family Life Sci 57(13), 1249–65.

    Article  PubMed  CAS  Google Scholar 

  7. Williams, E.D., Sandler, M. (1963) The classification of carcinoid tumors Lancet 1, 238–9.

    Article  PubMed  CAS  Google Scholar 

  8. Solcia, E., Klöppel, G., Sobin, L. (2000) Histological typing of endocrine tumors, 2nd edition. Berlin, Heidelberg Springer Verlag.

    Google Scholar 

  9. Pacak, K., Eisenhofer, G., Goldstein, D.S. (2004) Functional imaging of endocrine tumors: role of positron emission tomography Endocr Rev 25(4), 568–80.

    Article  PubMed  Google Scholar 

  10. Lamberts, S.W., Bakker, W.H., Reubi, J.C., Krenning, E.P. (1990) Somatostatin-receptor imaging in the localization of endocrine tumors N Engl J Med 323(18), 1246–9.

    Article  PubMed  CAS  Google Scholar 

  11. Brown, R.S., Wahl, R.L. (1993) Overexpression of Glut-1 glucose transporter in human breast cancer. An immunohistochemical study Cancer 72(10), 2979–85.

    Article  PubMed  CAS  Google Scholar 

  12. Adams, S., Baum, R.P., Hertel, A., Schumm-Drager, P.M., Usadel, K.H., Hor, G. (1998)Metabolic (PET) and receptor (SPET) imaging of well- and less well-differentiatedtumors: comparison with the expression of the Ki-67 antigen Nucl Med Commun 19(7), 641–7.

    Article  PubMed  CAS  Google Scholar 

  13. Adams, S., Baum, R., Rink, T., Schumm-Drager, P.M., Usadel, K.H., Hor, G. (1998) Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumors Eur J Nucl Med 25(1), 79–83.

    Article  PubMed  CAS  Google Scholar 

  14. Hoegerle, S., Altehoefer, C., Ghanem, N., Brink, I., Moser, E., Nitzsche, E. (2001) 18F-DOPA positron emission tomography for tumor detection in patients with medullary thyroid carcinoma and elevated calcitonin levels Eur J Nucl Med 28(1), 64–71.

    Article  PubMed  CAS  Google Scholar 

  15. Kok, J., Lin, M., Wong, V., et al. (2008) (18F)FDG PET-CT in pancreatic neuroendocrine tumors associated with von Hippel Lindau Syndrome Clin Endocrinol 70(4), 657–9.

    Article  Google Scholar 

  16. Belhocine, T., Foidart, J., Rigo, P., et al. (2002) Fluorodeoxyglucose positron emission tomography and somatostatin receptor scintigraphy for diagnosing and staging carcinoid tumors: correlations with the pathological indexes p53 and Ki-67 Nucl Med Commun 23, 727–34.

    Article  PubMed  CAS  Google Scholar 

  17. Diehl, M., Risse, J.H., Brandt-Mainz, K., et al. (2001) Fluorine-18 fluorodeoxyglucose positron emission tomography in medullary thyroid cancer:results of a multicentre study Eur J Nucl Med 28:(11), 1671–6.

    Article  PubMed  CAS  Google Scholar 

  18. Szakall, S., Jr., Esik, O., et al. (2002) 18F-FDG PET detection of lymph node metastases in medullary thyroid carcinoma J Nucl Med 43(1), 66–71.

    PubMed  Google Scholar 

  19. Rubello, D., Rampin, I., Nanni, C., et al. (2008) The role of 18F-FDG PET-CT in detecting metastatic deposits of recurrent medullary thyroid carcinoma: A prospective study Eur J Surg Oncol 34, 581–6.

    Article  PubMed  CAS  Google Scholar 

  20. Ong, S.C., Schröder, H., Patel, S.G., et al. (2007) Diagnostic accuracy of 18F-FDG PET in restaging patients with medullary thyroid carcinoma and elevated calcitonin levels J Nucl Med 48, 501–7.

    Article  PubMed  CAS  Google Scholar 

  21. Rufini, V., Treglia, G., Perotty, G., et al. (2008) Role of PET in medullary thyroid carcinoma Minerva Endocrinol 33, 67–73.

    PubMed  CAS  Google Scholar 

  22. Orlefors, H., Sundin, A., Garske, U.,et al. (2005) Whole-body (11)C-5-hydroxytryp­tophan positron emission tomography as a universal imaging technique for neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and computed tomography J Clin Endocrinol Metab 90(6), 3392–400.

    Article  PubMed  CAS  Google Scholar 

  23. Hoegerle, S., Altehoefer, C., Ghanem, N.,et al.(2001) Whole-body 18F dopa PET for detection of gastrointestinal carcinoid tumors Radiology 220(2), 373–80.

    PubMed  CAS  Google Scholar 

  24. Becherer, A., Szabo, M., Karanikas, G., et al. (2004) Imaging of advanced neuroendocrine tumors with (18)F-DOPA PET J Nucl Med 45, 1161–7.

    PubMed  CAS  Google Scholar 

  25. Hoegerle, S., Nitzsche, E., Altehoefer, C., et al.(2002) Pheochromocytomas: detection with 18F DOPA whole body PET – initial results Radiology 222(2), 507–12.

    Article  PubMed  Google Scholar 

  26. Hoegerle, S., Ghanem, N., Altehoefer, C.,et al.(2003) 18F-DOPA positron emission tomography for the detection of glomus tumors Eur J Nucl Med Mol Imaging 30(5), 689–94.

    Article  PubMed  CAS  Google Scholar 

  27. Örlefors, H., Sundin, A., Ahlström, H., et al. (1998) Positron emission tomography with 5-hydroxytryptophan in neuroendocrine tumors J Clin Oncol 16, 2534–42.

    PubMed  Google Scholar 

  28. Sundin, A., Eriksson, B., Bergström, M., et al. (2004) PET in the diagnosis ofneuroendocrine tumors Ann NY Acad Sci 1014, 246–57.

    Article  PubMed  CAS  Google Scholar 

  29. Orlefors, H., Sundin, A., Lu, L.,et al.(2006) Carbidopa pretreatment improves image interpretation and visualization of carcinoid tumors with 11C-5-hydroxytryptophan positron emission tomography Eur J Nucl Med Mol Imaging 33(1), 60–5.

    Article  PubMed  CAS  Google Scholar 

  30. Koopmans, K., Neels, O., Kema, I., et al. (2008) Improved staging of patients with carcinoid and islet cell tumors with 18F-dihydroxy-Phenyl-alanine and 11C-5-Hydroxy-Tryptophan positron emission tomography J Clin Oncol 26, 1489–1495.

    Article  PubMed  Google Scholar 

  31. Ilias, I., Yu, J., Carrasquillo, J.A.,et al. (2003) Superiority of 6-[18F]-fluorodopamine positron emission tomography versus [131I]- metaiodobenzylguanidine scintigraphy in the localization of metastatic pheochromocytoma J Clin Endocrinol Metab 88(9), 4083–7.

    Article  PubMed  CAS  Google Scholar 

  32. Ilias, I., Chen, C.C., Carrasquillo, J.A., et al. (2008) Comparison of 6-18F-fluorodopamine PET with 123I-metaiodobenzylguanidine and 111In-pentreotide scintigraphy in localization of nonmetastatic and metastatic pheochromocytoma. J Nucl Med 49(10), 1613–9.

    Article  PubMed  Google Scholar 

  33. Kaji, P., Carrasquillo, J.A., Linehan, M.W., et al. (2007) The role of 6-(18F)fluorodopamine positron emission tomography in the localization of adrenal pheochromocytoma associated with von Hippel-Lindau syndrome Eur J Endocrinol 156, 483–7.

    Article  PubMed  CAS  Google Scholar 

  34. Shulkin, B.L., Wieland, D.M., Schwaiger, M.,et al.(1992) PET scanning with hydroxyephedrine: an approach to the localization of pheochromocytoma J Nucl Med 33(6), 1125–31.

    PubMed  CAS  Google Scholar 

  35. Trampal, C., Engler, H., Juhlin, C., Bergstrom, M., Langstrom, B. (2004) Pheochromocytomas: detection with 11C hydroxyephedrine PET Radiology 230(2), 423–8.

    Article  PubMed  Google Scholar 

  36. Mann, G.N., Link, J.M., Pham, P.,et al.(2006) [11C]metahydroxyephedrine and [18F]fluorodeoxyglucose positron emission tomography improve clinical decision making in suspected pheochromocytoma Ann Surg Oncol 13(2), 187–97.

    Article  PubMed  Google Scholar 

  37. Bergstrom, M., Bonasera, T.A., Lu, L.,et al.(1998) In vitro and in vivo primate evaluation of carbon-11-etomidate and carbon-11-­metomidate as potential tracers for PET imaging of the adrenal cortex and its tumors J Nucl Med 39(6), 982–9.

    PubMed  CAS  Google Scholar 

  38. Bergstrom, M., Juhlin, C., Bonasera, T.A.,et al.(2000) PET imaging of adrenal cortical tumors with the 11beta-hydroxylase tracer 11C-metomidate J Nucl Med 41(2), 275–82.

    PubMed  CAS  Google Scholar 

  39. Hennings, J., Lindhe, O., Bergstrom, M., Langstrom, B., Sundin, A., Hellman, P. (2006) [11C]metomidate positron emission tomography of adrenocortical tumors in correlation with histopathological findings J Clin Endocrinol Metab 91(4), 1410–4.

    Article  PubMed  CAS  Google Scholar 

  40. Hennings, J., Hellman, P., Ahlström, H., et al. (2007) Computed tomography, magnetic resonance imaging and 11C-metomidate positron emission tomography for evaluation of adrenal incidentalomas Eur J Radiol 69(2), 314–23.

    Article  PubMed  Google Scholar 

  41. Oliveira, P.G., Brenol, C.K., Edelweiss, M. et al. (2008) Effect of an antagonist of the bombesin/gastrin releasing peptide receptor on complete Freund’s adjuvant-induced arthritis in rats Peptides 29(10),1726–31.

    Article  PubMed  CAS  Google Scholar 

  42. Krenning, E.P., Bakker, W.H., Breeman, W.A.,et al. (1989) Localization of endocrine-related tumors with radioiodinated analogue of somatostatin Lancet 1(8632), 242–4.

    Article  PubMed  CAS  Google Scholar 

  43. Valkema, R., Pauwels, S., Kvols, L.K.,et al.(2006) Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0,Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors Semin Nucl Med 36(2), 147–56.

    Article  PubMed  Google Scholar 

  44. Antunes, P., Ginj, M., Zhang, H., et al. (2007) Are radiogallium-labelled DOTA- conjugated somatostatin analogues superior to those labeled with other radiometals Eur J Nucl Med Mol Imaging 34(7), 982–93.

    Article  PubMed  CAS  Google Scholar 

  45. Henze, M., Schuhmacher, J., Hipp, P.,et al.(2001) PET imaging of somatostatin receptors using [68Ga]DOTA-D-Phe1-Tyr3-octreotide: first results in patients with meningiomas J Nucl Med 42(7), 1053–6.

    PubMed  CAS  Google Scholar 

  46. Hofmann, M., Maecke, H., Borner, R.,et al.(2001) Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: preliminary data Eur J Nucl Med 28(12), 1751–7.

    Article  PubMed  CAS  Google Scholar 

  47. Kowalski, J., Henze, M., Schuhmacher, J., Macke, H.R., Hofmann, M., Haberkorn, U. (2003)Evaluation of positron emission tomography imaging using [68Ga]-DOTA-D Phe(1)-Tyr(3)-Octreotide in comparison to [111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors Mol Imaging Biol 5(1), 42–8.

    Article  PubMed  Google Scholar 

  48. Henze, M., Dimitrakopoulou-Strauss, A., Milker-Zabel, S.,et al.(2005) Characterization of 68Ga-DOTA-D-Phe1-Tyr3-octreotide kin­etics in patients with meningiomas J Nucl Med 46(5), 763–9.

    PubMed  CAS  Google Scholar 

  49. Buchmann, I., Henze, M., Engelbrecht, S.,et al.(2007) Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumors Eur J Nucl Med Mol Imaging 34(10), 1617–26.

    Article  PubMed  CAS  Google Scholar 

  50. Fanti, S., Ambrosini, V., Tomassetti, P., et al. (2008) Evaluation of unusual neuroendocrine tumors by means of 68Ga-DOTA-NOC PET Biomed Pharmacother 62, 667–71.

    Article  PubMed  CAS  Google Scholar 

  51. Ambrosini, V., Tomassetti, P., Castellucci, P., et al. (2008) Comparison between 68Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumors Eur J Nucl Med Mol Imaging 35, 1431–8.

    Article  PubMed  CAS  Google Scholar 

  52. Von Schulthess, G.K., Steinert, H.C., Hany, T.F. (2006) Integrated PET-CT: current applications and future directions. Radiology 238(2), 405–22.

    Article  Google Scholar 

  53. Mottaghy, F.M., Sunderkotter, C., Schubert, R.,et al.(2007) Direct comparison of[18F]FDG PET-CT with PET alone and with side-by-side PET and CT in patients with malignant melanoma Eur J Nucl Med Mol Imaging 34(9), 1355–64.

    Article  PubMed  Google Scholar 

  54. Beyer, T., Townsend, D.W., Brun, T.,et al.(2000) A combined PET-CT scanner for clinical oncology J Nucl Med 41(8), 1369–79.

    PubMed  CAS  Google Scholar 

  55. Mottaghy, F.M., Reske, S.N. (2006) Func-tional imaging of neuroendocrine tumors with PET Pituitary 9(3), 237–42.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Nuclear Medicine, University Hospital Leuven, Leuven, Belgium

    Sofie Van Binnebeek & Felix M. Mottaghy

  2. Department of Endocrinology, University Hospital Aachen, Aachen, Germany

    Wolfram Karges

Authors
  1. Sofie Van Binnebeek
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Wolfram Karges
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Felix M. Mottaghy
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Felix M. Mottaghy .

Editor information

Editors and Affiliations

  1. Dept. Radiology, University of Iowa, Hawkins Drive 200, Iowa City, 52242-1009, Iowa, USA

    Malik E. Juweid

  2. , Dept. Nuclear Medicine & PET Research, VU University Medical Centre, De Boelelaan 1117, Amsterdam, 1081 HV, Netherlands

    Otto S. Hoekstra

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Humana Press

About this protocol

Cite this protocol

Van Binnebeek, S., Karges, W., Mottaghy, F.M. (2011). Functional Imaging of Neuroendocrine Tumors. In: Juweid, M., Hoekstra, O. (eds) Positron Emission Tomography. Methods in Molecular Biology, vol 727. Humana Press. https://doi.org/10.1007/978-1-61779-062-1_7

Download citation

  • DOI: https://doi.org/10.1007/978-1-61779-062-1_7

  • Published:

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-61779-061-4

  • Online ISBN: 978-1-61779-062-1

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation